Neuron Bio develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas. Its pharma division is mainly devoted to the search of drugs for the prevention and treatment of neurodegenerative diseases, particularly for the Alzheimer’s disease. The diagnostic division develops tools and biomarkers for the diagnosis of human diseases, principally for those of the Central Nervous System as the Alzheimer’s disease. Its service division develops research projects for public institutions and for companies of the pharmaceutical, biotechnological, agro-food and animal health area. It offers consultancy services as well.
- Business Type:
- Industry Type:
- Chemical & Pharmaceuticals - Pharmaceutical
- Market Focus:
- Internationally (various countries)
- Year Founded:
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Neuron Bio owns a broad and diverse high value molecule collection, neuroprotective compounds, 5 patent applications (3 of them granted by the European Union and other 2 in USA) and exclusive platforms for drug discovery and development.
Neol Bio, a subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.
Neuron and Neol have facilities, laboratories and cutting-edge equipment in the biotechnology field, clean rooms, rodent and zebrafish facilities, and also an own pilot plant for demonstration of the developed processes.
They have a highly qualified team of researchers with wide experience in R&D and renowned prestige in the sector, who participate actively in numerous scientific projects, in which the company has already invested over €30 million.
Neuron Bio has facilities in Granada and Madrid that are connected with university research centers and is quoted on the Alternative Stock Market (MAB) in Spain.
The mission of Neuron Bio is the development of diagnostic tools, drug discovery and R&D services for the nervous system.
To become an international point of reference in the field of Alzheimer’s disease in the coming 5 years…
2005: Foundation of the company in Spain.
2006: Design and installation of laboratories and offices in Granada.
2010: Neuron Bio goes public trading in the Spanish Alternative Stock Market in the growth companies sector (MAB-EE), being the first biotech company to join the alternative market.
2012: Creation of Neol BioSolutions SA (Neol Bio) a 50:50 joint venture with Repsol.
2013: Inauguration of its facilities in Madrid from which the international expansion is boosted.
2014: Purchase of 50% Neol to Repsol. Neuron Bio owns 100% Neol Biosolutions.
Neuron Bio has become one of the business projects of reference in the Spanish biotech sector, endorsed by numerous national and international awards and recognition.
2015: SME Prize in the category of Technological Innovation awarded by Expansión and IFEMA
2014: Health Sciences Prize X Edition of the Granada Caja Rural Foundation
2013: Prize Andalucía Research. Junta de Andalucía
2012: Parkinson Prize for Solidarity awarded by the Granada Parkinson’s Association
2012: Andalucian Prize for the Promotion of Scientific and Technical Research
2011: Emprendedor XXI prize in Andalucía
2010: Business Trajectory of an Innovative Technological Company awarded within the IV National Prizes by the National Association of the European Network of Centers for Innovative Businesses (ANCES)
2010: Flag of Andalucía awarded by the Andalusian regional government
2009: IDEAL prize
2009: Seal for Innovation 2009, awarded by the Association of Spanish Science and Technology Parks
2009: Prize for Business Excellence awarded by the Andalusian regional government